Search clinical trials for: Angiotensin type II receptor antagonists

Total 11191 results

Kumamoto University

Terminated

Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Hypertension

Japan
Boehringer Ingelheim

Completed

Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension

Hypertension
Boehringer Ingelheim

Completed

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Hypertension
Novartis

Completed

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

Hypertension

Germany
Novartis

Completed

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Hypertension

Switzerland
University of Campania "Luigi Vanvitelli"

Completed

Telmisartan in Haemodialysis Patients With Chronic Heart Failure

Heart Failure, Congestive

Italy
Novartis

Completed

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

Healthy

United States
Novartis

Completed

To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers

Healthy

India
Celltrion Pharm, Inc.

Completed

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Essential Hypertension

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The DDI Study of SP2086 and Valsartan

Type 2 Diabetes

China
Takeda

Completed

A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet

Hypertension

Japan
LG Life Sciences

Completed

Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of
University of California, Los Angeles
The Campbell Foundation

Completed

A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease

Endothelial Dysfunction

United States
Novartis

Completed

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

Hypertension | Diastolic Dysfunction

United States
Samsung Medical Center

Unknown

The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria

Proteinuria | Chronic Kidney Disease

Korea, Republic of
Charles University, Czech Republic
AstraZeneca

Unknown

CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Czech Republic
Asker & Baerum Hospital
Ullevaal University Hospital; AstraZeneca; Helse Ost

Completed

Candesartan in the Prevention of Relapsing Atrial Fibrillation

Atrial Fibrillation

Norway
Karolinska University Hospital
AstraZeneca

Unknown

Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy

Diabetes, Type I

Sweden
Takeda

Completed

A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure

Hypertension

Japan
Palo Alto Veterans Institute for Research
Medtronic; James Cook University, Queensland, Australia

Completed

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms (TEDY)

Abdominal Aortic Aneurysm

United States
Roxane Laboratories

Completed

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

Hypertension

United States
Ain Shams University

Completed

Chronopharmacology of Valsartan in Normotensive Subjects

Healthy Normotensive Volunteers

Egypt
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Valsartan

Type 2 Diabetes

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Congestive Heart Failure

Netherlands, Portugal, Spain, United States, Belgium, Italy, Argentina, Brazil, Canada, France, Germany, Mexico, South Africa, Sweden, Australia, Russian Federation, Poland, Czech Republic, Denmark, Ireland, Hungary, Switzerland, Gr... and more
Karin Skov
AstraZeneca; University of Aarhus

Unknown

Danish Hypertension Prevention Project - DHYPP

Hypertension

Denmark
Fundación Cardiovascular de Colombia
AstraZeneca

Terminated

Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects (ARAMIA)

Obesity | Glucose Intolerance

Colombia
Seung-Jung Park
Novartis

Completed

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent (VAL-SUPPRES)

Coronary Artery Disease

Korea, Republic of
Osaka City University

Completed

Prevention of CHOP-induced Chronic Cardiotoxicity

Non-Hodgkin's Lymphoma

Japan
Sanofi
Bristol-Myers Squibb

Completed

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

Hypertension

United States
Steno Diabetes Center Copenhagen

Completed

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Type 2 Diabetes | Microalbuminuria

Denmark
Rambam Health Care Campus

Unknown

Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

NIDDM

Israel
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Essential Hypertension

China
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Samsung Medical Center

Recruiting

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Breast Cancer | Cardiotoxicity | Prevention | Adjuvant | Trastuzumab

Korea, Republic of
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Cardiorenal Syndrome (CRS)

United States
Takeda

Completed

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

Hypertension

Japan
Boehringer Ingelheim

Completed

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Hypertension
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Healthy

India
Boehringer Ingelheim

Completed

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Hypertension
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials (DIRECT)

Type 2 Diabetes
National Taiwan University Hospital
Daiichi Sankyo Taiwan Ltd.

Completed

Evaluation of Effects of Exercise Training and ARB in DM Patients

Exercise Training | Vascular Function

Taiwan
Novartis

Completed

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Hypertension | Type 2 Diabetes | PROTEINURIA
Novartis

Completed

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Hypertension | Dyslipidemia

Russian Federation
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

Congestive Heart Failure
Gruppo di Ricerca GISSI

Completed

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Atrial Fibrillation

Italy, Switzerland
Novartis Pharmaceuticals

Terminated

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Hypertension | Diabetic Nephropathy

Switzerland
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
Hackensack Meridian Health

Terminated

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

GVHD

United States
The University of Texas Health Science Center,...

Withdrawn

Candesartan as an Adjunctive Treatment for Bipolar Depression

Bipolar Disorder Depression

United States

3

Subscribe